摘要
目的:探讨在多重耐药鲍曼不动杆菌肺炎的治疗上,头孢哌酮钠舒巴坦钠、替加环素的临床价值。方法:将我院诊治的多重耐药鲍曼不动杆菌肺炎患者(共76例)依照就诊顺序的前后不同随机分成2组(例数一致),其中,参照组接受头孢哌酮钠舒巴坦钠治疗,实验组接受头孢哌酮钠舒巴坦钠、替加环素联合治疗,对2组患者的治疗成效予以评价。结果:实验组的总有效率(86.84%)显著高于参照组(63.16%),差异具有统计学意义(P<0.05);实验组用药后的C反应蛋白(CRP)、降钙素原(PCT)、白细胞计数(WBC)均显著低于参照组,差异有统计学意义(P<0.05);实验组的不良反应发生率(15.78%)与参照组(13.15%)对比,差异无统计学意义(P<0.05)。结论:在多重耐药鲍曼不动杆菌肺炎的治疗上,头孢哌酮钠舒巴坦钠、替加环素联合应用的效果突出,且安全性良好。
Objective:To investigate the clinical value of cefoperazone sodium sulbactam sodium and tegicycline in the treatment of multidrug resistant Acinetobacter baumannii pneumonia.Methods:76 patients with Acinetobacter baumannii pneumonia who were treated in our hospital were randomly divided into two groups according to the order of visit.The control group was treated with cefoperazone sodium sulbactam sodium.The experimental group was treated with cefoperazone sodium sulbactam sodium and tegicycline.Results:The total effective rate of the experimental group(86.84%)was significantly higher than that of the control group(63.16%,P﹤0.05).The white blood cell count(WBC)of C-reactive protein(CRP),procalcitonin(PCT),in the experimental group was significantly lower than that in the control group(P﹤0.05),while the incidence of adverse reactions in the experimental group(15.78%)was not significantly higher than that in the control group(13.15%,P﹥0.05).Conclusion:In the treatment of multidrug resistant Acinetobacter baumannii pneumonia,cefoperazone sodium sulbactam sodium and tegicycline are effective and safe.
作者
刘培培
赵江
LIU Pei-pei;ZHAO Jiang(Department of Respiratory Medicine,Nanyang Central Hospital,Nanyang Henan 473000,China)
出处
《药品评价》
CAS
2019年第1期24-27,共4页
Drug Evaluation
基金
河南省卫生科技创新型人才工程(201003040)
关键词
替加环素
头孢哌酮钠舒巴坦钠
多重耐药鲍曼不动杆菌肺炎
对比研究
Tigicycline
Cefoperazone Sodium Sulbactam Sodium
Multidrug Resistant Acinetobacter Baumannii Pneumonia
Comparative Study
